- April 26, 2018
2:15 pm - 3:30 pm
This live symposium held in conjunction with the National Lipid Association 2018 Scientific Sessions will outline the role of PCSK9 inhibitor therapeutics in preventing heart attack and stroke in a new era of preventive cardiology. The expert faculty will review risk stratification for patients with cardiovascular disease (CVD). Cardiovascular outcomes data from ODYSSEY and FOURIER PCSK9 inhibitor clinical trials will be analyzed, utilizing an interactive panel format to translate evidence-based medicine to clinical decision making. The faculty will evaluate best practices for optimally managing preventive cardiology with PCSK9 inhibitor therapeutics.
2:15 – 2:30 pm – Welcome and Introductions
2:30 – 2:40 pm – Accurate Assessment of CVD Risk
2:40 – 2:45 pm – Interactive Panel Discussion
2:45 – 2:55 pm – ODYSSEY Outcomes Trial Data
2:55 – 3:05 pm – FOURIER Trial Data
3:05 – 3:15 pm – Interactive Panel Discussion
3:15 – 3:25 pm – Applying Advanced Lipid Science to Clinical Practice
3:25 – 3:30 pm – Interactive Panel Discussion and Conclusion
This activity is designed to meet the needs of cardiologists, lipidologists, primary care physicians, nurse practitioners, nurses, pharmacists, dietitians and other healthcare professionals involved in the management of patients with or at risk for cardiovascular disease.
- Recognize the accurate assessment of cardiovascular disease risk across all patient populations
- Analyze the clinical trial and real world data that supports the role of PCSK9 therapeutics for the prevention of heart attack and stroke
- Appraise the use of PCSK9 therapeutics through case studies
- Discuss strategies to improve the knowledge, skills or performance of the healthcare team
JW Marriott Las Vegas – Marquis Ballroom 4-8
21 N Rampart Blvd, Las Vegas, NV 89145
Thursday, April 26th, 2018
Registration and Refreshments: 2:15 pm – 2:30 pm
CME/CE Program: 2:30 pm – 3:30 pm
There is no fee for this educational activity.